Latest Ratios: P/E Ratio 31.8x · EV/EBITDA 18.5x · ROE 17.6%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $22.8B | $20.5B | $25.9B | $23.4B | $19.9B | $25.6B | $22.0B | $17.7B | $16.5B | $12.8B | $11.6B |
| Enterprise Value | $24.5B | $22.3B | $27.3B | $25.7B | $22.4B | $28.1B | $24.2B | $19.8B | $18.3B | $14.9B | $12.5B |
| P/E Ratio → | 31.80 | 27.76 | 44.18 | 31.00 | 47.98 | 30.87 | 27.96 | 28.83 | 28.97 | 17.30 | 25.25 |
| P/S Ratio | 3.67 | 3.30 | 4.23 | 3.99 | 3.69 | 4.93 | 4.49 | 4.07 | 3.98 | 3.40 | 3.32 |
| P/B Ratio | 5.86 | 5.12 | 5.93 | 6.07 | 5.69 | 7.91 | 7.28 | 6.65 | 6.72 | 5.79 | 5.86 |
| P/FCF | 20.82 | 18.74 | 26.48 | 29.01 | 28.11 | 29.24 | 24.68 | 22.42 | 23.44 | 20.19 | 19.13 |
| P/OCF | 18.72 | 16.85 | 22.36 | 22.72 | 22.43 | 25.74 | 22.21 | 20.51 | 21.59 | 18.85 | 17.67 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.59 | 4.47 | 4.38 | 4.17 | 5.41 | 4.94 | 4.54 | 4.41 | 3.96 | 3.58 |
| EV / EBITDA | 18.53 | 16.82 | 26.09 | 20.02 | 27.46 | 21.63 | 19.82 | 19.48 | 19.59 | 17.42 | 15.05 |
| EV / EBIT | 22.78 | 21.18 | 32.06 | 23.81 | 36.60 | 25.85 | 23.36 | 23.37 | 22.88 | 20.05 | 17.06 |
| EV / FCF | — | 20.38 | 27.95 | 31.81 | 31.75 | 32.09 | 27.12 | 25.04 | 25.99 | 23.48 | 20.67 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.7% | 44.7% | 45.7% | 44.1% | 41.9% | 43.6% | 45.2% | 45.5% | 44.4% | 45.8% | 45.5% |
| Operating Margin | 17.4% | 17.4% | 13.2% | 18.0% | 11.1% | 20.8% | 21.0% | 19.3% | 19.1% | 19.4% | 20.7% |
| Net Profit Margin | 11.9% | 11.9% | 9.6% | 12.9% | 7.7% | 15.9% | 16.1% | 14.1% | 13.7% | 19.7% | 13.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 17.6% | 17.6% | 14.2% | 20.6% | 12.3% | 26.5% | 27.6% | 24.1% | 24.3% | 35.4% | 22.9% |
| ROA | 8.3% | 8.3% | 6.7% | 8.9% | 5.1% | 10.7% | 11.2% | 9.7% | 9.4% | 14.3% | 10.7% |
| ROIC | 13.9% | 13.9% | 10.2% | 13.0% | 7.6% | 14.8% | 15.6% | 14.0% | 13.9% | 15.2% | 19.2% |
| ROCE | 14.4% | 14.4% | 11.0% | 14.8% | 9.1% | 18.1% | 17.8% | 16.3% | 16.1% | 17.4% | 21.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.55 | 0.55 | 0.55 | 0.68 | 0.82 | 0.85 | 0.78 | 0.83 | 0.86 | 1.07 | 0.57 |
| Debt / EBITDA | 1.66 | 1.66 | 2.30 | 2.03 | 3.49 | 2.11 | 1.93 | 2.19 | 2.26 | 2.77 | 1.35 |
| Net Debt / Equity | — | 0.45 | 0.33 | 0.59 | 0.74 | 0.77 | 0.72 | 0.78 | 0.73 | 0.94 | 0.47 |
| Net Debt / EBITDA | 1.36 | 1.36 | 1.38 | 1.76 | 3.15 | 1.92 | 1.78 | 2.03 | 1.92 | 2.44 | 1.12 |
| Debt / FCF | — | 1.64 | 1.48 | 2.80 | 3.65 | 2.85 | 2.44 | 2.61 | 2.55 | 3.29 | 1.54 |
| Interest Coverage | 11.05 | 11.05 | 8.96 | 9.72 | 6.84 | 19.93 | 16.96 | 11.51 | 10.06 | 14.17 | 26.48 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | 1.07 | 1.70 | 1.08 | 1.18 | 0.59 | 0.80 | 0.88 | 0.81 | 1.07 | 0.76 |
| Quick Ratio | 0.71 | 0.71 | 1.24 | 0.64 | 0.63 | 0.34 | 0.44 | 0.49 | 0.52 | 0.72 | 0.50 |
| Cash Ratio | 0.27 | 0.27 | 0.73 | 0.24 | 0.23 | 0.12 | 0.13 | 0.14 | 0.24 | 0.30 | 0.19 |
| Asset Turnover | — | 0.70 | 0.69 | 0.68 | 0.64 | 0.65 | 0.66 | 0.65 | 0.68 | 0.63 | 0.80 |
| Inventory Turnover | 6.41 | 6.41 | 5.41 | 5.35 | 4.83 | 5.47 | 5.41 | 5.69 | 6.02 | 6.19 | 7.37 |
| Days Sales Outstanding | — | 34.92 | 35.91 | 32.77 | 28.65 | 28.52 | 29.73 | 29.85 | 30.40 | 33.43 | 29.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.2% | 1.4% | 1.1% | 1.1% | 1.3% | 1.0% | 1.1% | 1.3% | 1.3% | 1.5% | 1.6% |
| Payout Ratio | 39.0% | 39.0% | 47.3% | 35.3% | 61.6% | 29.9% | 30.2% | 36.4% | 37.5% | 25.6% | 39.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 3.6% | 2.3% | 3.2% | 2.1% | 3.2% | 3.6% | 3.5% | 3.5% | 5.8% | 4.0% |
| FCF Yield | 4.8% | 5.3% | 3.8% | 3.4% | 3.6% | 3.4% | 4.1% | 4.5% | 4.3% | 5.0% | 5.2% |
| Buyback Yield | 4.0% | 4.4% | 0.0% | 1.3% | 0.0% | 2.0% | 1.4% | 1.4% | 1.2% | 3.1% | 3.5% |
| Total Shareholder Yield | 5.2% | 5.8% | 1.1% | 2.4% | 1.3% | 2.9% | 2.4% | 2.7% | 2.5% | 4.6% | 5.0% |
| Shares Outstanding | — | $244M | $247M | $248M | $246M | $250M | $252M | $252M | $251M | $256M | $262M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CHD stock.
Church & Dwight Co., Inc.'s current P/E ratio is 31.8x. The historical average is 25.1x. This places it at the 93th percentile of its historical range.
Church & Dwight Co., Inc.'s current EV/EBITDA is 18.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.1x.
Church & Dwight Co., Inc.'s return on equity (ROE) is 17.6%. The historical average is 19.2%.
Based on historical data, Church & Dwight Co., Inc. is trading at a P/E of 31.8x. This is at the 93th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Church & Dwight Co., Inc.'s current dividend yield is 1.22% with a payout ratio of 39.0%.
Church & Dwight Co., Inc. has 44.7% gross margin and 17.4% operating margin. Operating margin between 10-20% is typical for established companies.
Church & Dwight Co., Inc.'s Debt/EBITDA ratio is 1.7x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Margin compression from input costs
Metrics are mathematically derived from official filings.
Margin Resilience Amidst Cost Pressures
Gross margin held near 45% in 2026Q2, per reported figures, despite commodity inflation, but operating margin compressed to 18.1% from 20.1% a year earlier, indicating SG&A inflation is eroding profitability.
The stability of gross margin around 45% suggests the company's value-tier positioning and brand elasticity provide some pricing power, yet the sequential decline in operating margin from 20.1% in 2025Q1 to 18.1% in 2026Q2 points to rising promotional spending and logistics costs. Net margin of 13.3% in 2026Q2 remains respectable but is below the 15%+ levels seen in early 2025, implying that the earnings quality is being diluted by non-operating items. Investors should monitor whether the recent Hero Cosmetics and TheraBreath acquisitions can lift blended margins toward the higher personal care segment, as the current trajectory suggests a temporary plateau.
ROIC Stability Masks Acquisition Drag
ROIC has hovered between 3.1% and 4.1% over the past ten quarters, per financial statements, reflecting a stable but modest return on invested capital, with the 2024Q3 dip to -1.1% highlighting one-time charges.
The narrow range of ROIC suggests that the company's asset-light model and brand investments are generating consistent returns, but the absolute level is low relative to peers like Clorox or Colgate, which may indicate that recent acquisitions have not yet been fully integrated to drive incremental returns. The negative ROIC in 2024Q3 was driven by a one-time charge, underscoring that reported returns can be distorted by non-recurring items. As the company continues to acquire brands at higher multiples, the sustainability of ROIC will depend on whether these brands can achieve the same margin and growth profile as the core Arm & Hammer franchise.
Working Capital Efficiency Tightens
Cash conversion cycle improved to 17 days in 2026Q2 from 29 days a year earlier, according to reported data, driven by a reduction in days inventory outstanding and stable payables, indicating better working capital management.
The improvement in CCC is notable, as DIO fell from 70 days in 2024Q2 to 64 days in 2026Q2, while DPO remained elevated near 82 days, suggesting the company is leveraging its supplier relationships to finance operations. However, the quick ratio of 0.69 in 2026Q2 indicates that inventory is a significant component of current assets, and any slowdown in demand could strain liquidity. The asset turnover of 0.17 is consistent with the company's brand-centric model, where intangible assets dominate the balance sheet, but it also implies that efficiency gains must come from margin expansion rather than asset utilization.
Leverage Creeps Higher on Acquisition Debt
Debt-to-EBITDA rose to 9.49x in 2026Q2 from 6.10x in 2024Q2, per balance sheet data, while interest coverage remained above 8x, indicating that debt service is still manageable but leverage is increasing.
The sharp increase in D/EBITDA is partly due to lower EBITDA from margin compression, but it also reflects the company's continued reliance on debt to fund acquisitions like Hero Cosmetics. Interest coverage of 8.65x in 2025Q4 and 12.36x in 2026Q1 suggests that earnings are sufficient to cover interest expenses, but the trend is concerning if EBITDA continues to decline. The company's leverage is moderate relative to peers like Colgate, but the rising trend warrants monitoring, especially if the M&A pipeline requires additional debt financing.
Liquidity Cushion Thins as Cash Declines
Current ratio fell to 1.15 in 2026Q2 from 1.95 in 2025Q1, while cash dropped to $254.8M, per reported figures, indicating a shrinking liquidity buffer that could be strained under stress.
The decline in the current ratio is driven by a combination of lower cash balances and increased short-term debt, as the company has been deploying cash for acquisitions and share repurchases. The quick ratio of 0.69 suggests that the company relies heavily on inventory to meet short-term obligations, which could be problematic if demand weakens or if inventory becomes obsolete. While the company has access to credit markets, the thinning liquidity cushion reduces financial flexibility and increases vulnerability to unexpected shocks.
P/E Misleads on Growth Potential
The trailing P/E of 33.12 appears rich, but forward P/E of 26.60 suggests the market expects earnings growth, per valuation data, yet the company's organic growth is near-flat, indicating the multiple may be overstating future expansion.
The most commonly misapplied ratio for CHD is the P/E multiple, as it fails to account for the company's M&A-driven growth model and the significant amortization expenses that depress reported earnings. Adjusted for acquisition-related amortization, the effective P/E would be lower, but the market's premium valuation implies expectations of accelerating organic growth that have not materialized in recent quarters. Investors should instead focus on EV/EBITDA, which at 19.24x is more comparable to peers and better reflects the company's cash-generating ability, while also considering the potential for margin expansion from the personal care portfolio shift.